Gwendolyn Wu

Reporter

Gwendolyn is a reporter at BioPharma Dive covering biotech startups, venture capital and the ecosystem that supports them. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn co-directs the AAJA Voices Fellowship, and teaches at the California Scholastic Press Association summer workshop. She has degrees in history and sociology from the University of California at Santa Barbara.

Email [email protected]

Submit a tip to our team

261 articles by Gwendolyn Wu

Filter by month:

Flagship-backed Omega signals it’s headed toward bankruptcy
Feb. 4, 2025
Metsera, Maze secure combined $415 million in IPOs
Jan. 30, 2025
Cargo to drop lead CAR-T therapy, lay off staff after study setback
Jan. 30, 2025
Atalanta banks $97M to send RNAi drugs into the brain
Jan. 28, 2025
Ascentage prices first biotech IPO of 2025, raising $126M
Jan. 23, 2025
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
Jan. 16, 2025
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning
Jan. 14, 2025
5 questions facing emerging biotech in 2025
Jan. 14, 2025
JPM25: Deals, Summit’s bravado and gene therapy headwinds
Jan. 13, 2025
Tune raises $175M for hepatitis B medicine, epigenetic research
Jan. 12, 2025
Kidney disease drugmaker Maze files for IPO
Jan. 8, 2025
Orbis raises $93M to turn popular biologics into pills
Jan. 6, 2025
A venture firm breathes new life into an old NGM drug
Dec. 19, 2024
Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
Dec. 11, 2024
Gene therapy uptake in sickle cell stays slow, despite patient interest
Dec. 9, 2024
BioAge shares tumble after decision to halt obesity drug study
Dec. 7, 2024
Nuvig pulls in $161M to make better immune drugs
Dec. 5, 2024
Biotech startups are built on venture capital. Track funding rounds here.
Nov. 21, 2024
Versant startup sets out to make a new type of obesity drug
Nov. 21, 2024
Chasing new ‘checkpoints,’ startup Valora emerges from a Nobel winner’s lab
Nov. 20, 2024
Flagship, Pfizer alliance yields two more startup deals
Nov. 20, 2024
TRex Bio raises $84M to compete in crowded immune drug field
Nov. 13, 2024
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Nov. 12, 2024
An RNAi renaissance is creating a new generation of startups
Nov. 6, 2024
Evommune raises $115M to accelerate immune drug tests
Oct. 31, 2024
A new biotech, built around protein design, springs from David Baker’s lab
Oct. 30, 2024
With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs
Oct. 27, 2024
GPCR drugmaker Septerna amasses $288M in IPO
Oct. 24, 2024
J&J’s Asish Xavier on biotech’s rebound in a volatile era
Oct. 24, 2024
RNA editing: emerging from CRISPR’s shadow
Oct. 22, 2024
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
Oct. 10, 2024
AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines
Oct. 9, 2024
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
Oct. 7, 2024
With $115M more, Triveni accelerates immune drug work
Oct. 2, 2024
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
Oct. 1, 2024
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Sept. 26, 2024
BioAge prices $198M IPO, validating pivot to obesity drug research
Sept. 25, 2024
An Italian biotech gets $52M to advance pediatric gene therapies
Sept. 25, 2024
Nura Bio gets $68M, new CEO to advance ‘neuroprotective’ brain drugs
Sept. 17, 2024
ArsenalBio raises $325M in one of the year’s largest biotech funding rounds
Sept. 4, 2024
Cell and gene therapy investment, once booming, is now in a slump
Aug. 29, 2024
Versant’s Jerel Davis on build-to-buy deals and pharma investment
Aug. 26, 2024
Two antibody startups file for IPOs amid summer slump
Aug. 23, 2024
Versant reimagines its Chinook success with newest startup launch
Aug. 22, 2024
With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
Aug. 9, 2024
Biotech startup Airna raises $60M for RNA editing medicines
July 31, 2024
GSK leans on Flagship for help finding new drugs, vaccines
July 29, 2024
Autobahn raises $100M on investor interest in neuropsych drugs
July 24, 2024
Private biotech M&A surges amid difficult IPO market
July 22, 2024
Vertex taps Orum to hunt for better ‘preconditioning’ drugs
July 16, 2024
SciRhom pulls in $70M for a new type of immune disease drug
July 9, 2024
A London biotech raises $114M to hone a new ADC payload
July 8, 2024
Alumis cuts IPO size, but nets $250M for immune drug work
June 28, 2024
AbbVie expands its IBD prospects with $250M Celsius deal
June 27, 2024
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine
June 25, 2024
Roche partners with RNA editing biotech Ascidian
June 18, 2024
Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.
June 18, 2024
Versant debuts biotech working on ‘anger management for the immune system’
June 13, 2024
Foresite, a biotech venture firm, reloads with $900M fund
June 12, 2024
As biotech recovers, venture firms’ preferences appear to shift
June 6, 2024
Eli Lilly adds ALS drug prospect with QurAlis deal
June 3, 2024
CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs
May 30, 2024
SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca
May 22, 2024
AltruBio lands up to $225M after shift to immune drug research
May 21, 2024
Pheon rides wave of ADC interest with $120M financing
May 21, 2024
Investors put $400M into biotech licensing obesity drugs from China
May 16, 2024
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
May 13, 2024
Novo taps another Flagship startup in search for next obesity drugs
May 9, 2024
Prologue, Flagship’s newest startup, looks to mine viruses for new drugs
May 7, 2024
CG follows big IPO with new results for bladder cancer drug
May 3, 2024
Delphia starts up with $67M to make a new type of cancer drug
May 2, 2024
Enlaza gets JP Morgan, Regeneron backing for covalent biologics
April 30, 2024
Repertoire pivot pays dividends with Bristol Myers deal
April 29, 2024
Regeneron expands in gene editing with Mammoth deal
April 25, 2024
Endeavor pulls in $132M to back cancer, lung disease drugs
April 24, 2024
Canaan hires Pfizer executive, reels in $100M for biotech investing
April 17, 2024
Biotech landlord Alexandria on research clusters and the sector’s recovery
April 16, 2024
Biotech IPOs bounced back in first quarter, but backlog remains
April 12, 2024
Vertex to buy kidney disease drugmaker Alpine for $4.9B
April 10, 2024
Private biotech funding rises as venture firms deploy cash
April 8, 2024
Diagonal starts up with $128M to make better ‘activator’ antibody drugs
April 3, 2024
Ginkgo, in search of more cell therapy tools, buys another startup
April 2, 2024
Boundless Bio breaks IPO lull with $100M fundraise
March 28, 2024
SQZ, Portal founder Armon Sharei on starting over in biotech
March 26, 2024
Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off
March 21, 2024
Clasp launches with $150M and a plan for precision cancer immunotherapies
March 20, 2024
German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing
March 14, 2024
Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO
March 7, 2024
European VC Invivo readies its latest fund to back new biotechs
March 6, 2024
Sionna raises another $182M to challenge Vertex in cystic fibrosis
March 6, 2024
Biotech IPOs heated up to start 2024. Will the surge last?
March 5, 2024
Nocion, chasing GSK, pulls in $62M for chronic cough drug
March 4, 2024
FogPharma pulls in $145M to support cancer drug research
March 1, 2024
Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup
Feb. 28, 2024
Frontier gets $80M, Galapagos’ backing to make a better KRAS drug
Feb. 22, 2024
Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies
Feb. 16, 2024
Versant-backed Firefly Bio wants to make the next generation of ADCs
Feb. 15, 2024
ADC startup ProfoundBio, led by Seagen veterans, raises $112M
Feb. 13, 2024
Two GV investors on biotech’s reset and building their next drug startups
Feb. 13, 2024
Gene editing biotech Metagenomi pulls off nearly $94M IPO
Feb. 8, 2024
Venture firm Scion Life Sciences launches with $310M to back new biotechs
Feb. 7, 2024
Khosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery
Feb. 6, 2024
Brain drug developer Alto Neuroscience prices $129M IPO
Feb. 2, 2024
CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech
Jan. 24, 2024
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
Jan. 23, 2024
A South Korean investment firm starts first US biotech fund
Jan. 18, 2024
Recursion’s Chris Gibson on AI in biotech and ‘virtuous cycles’
Jan. 12, 2024
Venture funding, dealmaking slowed in biotech last year: Pitchbook
Jan. 11, 2024
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
Jan. 10, 2024
JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job
Jan. 8, 2024
5 questions facing emerging biotech in 2024
Jan. 8, 2024
Gene editing startup Metagenomi files for an IPO
Jan. 6, 2024
Intellia to lay off staff, cut some early research
Jan. 4, 2024
A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome
Jan. 4, 2024
Pivotal Life Sciences reloads with $389M, hunting for deals in a downturn
Dec. 18, 2023
At ASH, doctors acclaim new sickle cell gene therapies, but are cautious on details
Dec. 13, 2023
ASH23: Pharma branding, Editas’ high bar and clinical trial diversity
Dec. 11, 2023
Pfizer marks progress for successor sickle cell drug at ASH
Dec. 10, 2023
Bluebird gene therapy, now approved for sickle cell, shows durable benefit in study update
Dec. 9, 2023
BrainChild Bio spins out of Seattle Children’s to develop cancer drugs
Dec. 5, 2023
Flagship outlines plans to raise $3B for new fund
Nov. 30, 2023
Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024
Nov. 28, 2023
Flagship-backed microbiome biotech Evelo to shut down
Nov. 22, 2023
Quotient emerges from Flagship with plan to explore somatic mutations
Nov. 21, 2023
Roche’s Genentech partners with Nvidia in AI drug deal
Nov. 21, 2023
West Coast investor Red Tree on its San Diego expansion and staying bullish in biotech
Nov. 16, 2023
Ajinomoto spices up its biopharma business with gene therapy deal
Nov. 13, 2023
CAR-T biotech Cargo Therapeutics prices $281M IPO
Nov. 10, 2023
An obesity drug biotech gets buy-in from Eli Lilly, venture firms
Nov. 7, 2023
Bristol Myers pays $100M for a different kind of ADC
Nov. 6, 2023
Bioluminescence Ventures debuts with $477M to speed up drug discovery
Nov. 1, 2023
A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy
Oct. 31, 2023
Abingworth raises $356M to invest in late-stage drug development
Oct. 30, 2023
Triveni emerges from biotech merger with $92M for immune disease drugs
Oct. 26, 2023
An OrbiMed-backed biotech launches with $85M and plans for a new kind of DNA medicine
Oct. 24, 2023
Laronde, Senda Biosciences merge to create new Flagship company
Oct. 19, 2023
Intellia cleared by FDA to start Phase 3 test of gene editing treatment
Oct. 18, 2023
With $56M, a Mayo Clinic-backed startup takes aim at radiopharmaceutical roadblocks
Oct. 17, 2023
Novo’s Uli Stilz on biotech innovation and the future of diabetes drugs
Oct. 17, 2023
A decade later, biotech’s CRISPR revolution is still going strong
Oct. 11, 2023
UniQure lays off 20% of staff, cuts research to ‘significantly’ lower costs
Oct. 5, 2023
How biotech IPOs performed in the third quarter
Oct. 3, 2023
Novo Nordisk, Evotec partner in metabolic disease drug discovery pact
Sept. 26, 2023
Intarcia’s diabetes drug-device combo voted down again by FDA panel
Sept. 21, 2023
Genentech takes up a deal to make ‘molecular glue’ drugs
Sept. 20, 2023
Startup Airna emerges from stealth to bring RNA editing to a rare disease
Sept. 19, 2023
RayzeBio, Neumora price some of biotech’s largest IPOs this year
Sept. 14, 2023
Flagship-backed Generate raises $273M as its first drugs move to the clinic
Sept. 14, 2023
With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’
Sept. 12, 2023
Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise
Sept. 6, 2023
Star Therapeutics adds another $90M to grow its galaxy of drug startups
Sept. 5, 2023
Intarcia, a former biotech unicorn, gets new life with startup deal
Aug. 30, 2023
Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt
Aug. 28, 2023
Neumora, a richly funded brain drug developer, readies for an IPO
Aug. 25, 2023
Radiopharmaceutical drugmaker RayzeBio signals plans to go public
Aug. 25, 2023
Foundery, a new biotech venture firm, sets out to speed early immune drug research
Aug. 22, 2023
In a year with few biotech IPOs, ‘crossover’ financings are hard to find
Aug. 16, 2023
Alltrna raises $109M for ‘transfer RNA’ drug vision
Aug. 9, 2023
Steve Jobs’ son raises $200M for cancer-focused venture fund
Aug. 2, 2023
Early-stage biotech funding on pace to drop 40% in 2023, HSBC report shows
July 28, 2023
European VC Medicxi raises $400M for ‘asset-centric’ biotech investing
July 27, 2023
Nexo allies with MD Anderson in pursuit of covalent cancer drugs
July 26, 2023
Editas names Biogen veteran as top scientist in latest executive change
July 24, 2023
Pfizer, Flagship join forces to hunt for 10 new drugs
July 18, 2023
Sanofi expands research deal with gene editing startup Scribe
July 17, 2023
Apogee, Sagimet price IPOs in positive sign for sluggish biotech market
July 14, 2023
Rupert Vessey, former Bristol Myers exec, to join Flagship as top scientist
July 13, 2023
‘It’s felt like Groundhog Day’: Biotech IPO slump drags on through 2023
July 6, 2023
F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn
June 30, 2023
Lilly to acquire cancer antibody drug startup Emergence
June 29, 2023
Startup Tagworks raises $65M to make ‘click-to-release’ cancer drugs
June 22, 2023
Flagship’s latest startup aims to take the guesswork out of small molecule drugs
June 21, 2023
Attovia, a new California biotech, launches with plans to rethink how drugs bind their targets
June 20, 2023
Cell and gene therapy manufacturing: the next generation of startups
June 20, 2023
Startup Eikon, led by Merck vets, buys drugs from three biotechs and banks another $106M
June 1, 2023
Atea rejects takeover bid from Concentra
May 30, 2023
Serial biotech founder Tim Springer on investing in startups and democratizing antibody research
May 26, 2023
Concentra bids on Atea, seeking to acquire another struggling biotech
May 23, 2023
ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs
May 23, 2023
Biotech Scribe strikes gene editing deal with Lilly subsidiary
May 16, 2023
Flagship’s newest startup is imitating nature to make new drugs
May 16, 2023
Nido debuts with $109M for its precision approach to brain drugs
May 15, 2023
FibroGen grabs an option to buy cancer drug startup Fortis
May 9, 2023
Recursion to acquire two Canadian drug discovery startups
May 8, 2023
Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021
May 4, 2023
Ovid partners with Waksal startup to develop drugs for rare brain disorders
May 1, 2023
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
May 1, 2023
A startup taking a different approach to Alzheimer’s gets fresh funds, Lilly backing
April 27, 2023
Orbital raises $270 million in biotech’s largest Series A round this year
April 26, 2023
GV’s Cathy Friedman on optimism in biotech and the pitches that make her wary
April 18, 2023
A stealth biotech startup is quietly advancing a new drugmaking tool from David Liu’s lab
April 5, 2023
New biotech investor Cure Ventures closes first fund, raising $350M
April 4, 2023
After an ‘amazing year,’ SR One raises $600M to fuel more drug startups
March 27, 2023
Biotech startups face ‘Series A cliff’ as venture capital stays cautious
March 24, 2023
At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders
March 22, 2023
With focus on fibrosis, startup Mediar draws big pharma backing
March 15, 2023
SVB’s failure was contained. Its effects on biotech could still linger.
March 14, 2023
Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’
March 14, 2023
Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug
March 9, 2023
Flagship’s latest startup emerges with a plan for ‘smarter biologics’
March 7, 2023
GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins
March 7, 2023
Amid industry turbulence, Chroma raises fresh funding to edit the epigenome
March 1, 2023
Biotech veteran Jodie Morrison on building drug ‘platforms’ and a support group for CEOs
Feb. 21, 2023
With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s delivery problem
Feb. 16, 2023
A new generation of biotech leaders is emerging. Can they change how drug startups are built?
Feb. 14, 2023
Another biotech IPO hits the market, as Mineralys raises $192M
Feb. 9, 2023
Magenta to explore sale, merger after study setback
Feb. 3, 2023
Biotech startup Structure pulls off rare IPO, raising $161M
Feb. 2, 2023
A startup launches with plans to open up a gene and cell therapy bottleneck
Jan. 31, 2023
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
Jan. 24, 2023
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Jan. 11, 2023
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Jan. 10, 2023
5 questions facing emerging biotech in 2023
Jan. 10, 2023
Sesen, Carisma merger plans draw shareholder opposition
Jan. 4, 2023
Belharra debuts with $130M in funding, Genentech partnership
Jan. 4, 2023
FDA halts planned trial of Entrada Duchenne drug
Dec. 20, 2022
A San Diego startup sees covalent biologics as the next frontier in cancer drugs
Dec. 15, 2022
Flagship’s Lovisa Afzelius on creating a successful biotech and a ‘very different’ startup market
Dec. 13, 2022
Dantari emerges with a new way to make cancer drug conjugates
Dec. 8, 2022
Star Therapeutics launches Vega, growing its galaxy of drug startups
Dec. 6, 2022
With $81M, Entact Bio takes a new approach to fixing helpful proteins
Dec. 6, 2022
Gene editing startup iECURE returns to investors for fresh funding
Nov. 30, 2022
CinCor shares dive after blood pressure drug fails key trial
Nov. 28, 2022
Cancer drugmaker Plexxikon gets new life as Opna Bio
Nov. 21, 2022
Former Rubius CEO to lead buzzy Flagship startup
Nov. 17, 2022
Jnana deepens ties with Roche and grabs a new round of funding
Nov. 15, 2022
After $250M Roche buyout, a startup plans a second strike with fresh funding
Nov. 15, 2022
Acrivon cuts IPO price to raise $99M for plan to revive old Lilly cancer drug
Nov. 15, 2022
Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs
Nov. 15, 2022
Third Rock-backed Faze Medicines shutters two years after launch
Nov. 10, 2022
Artiva cancels IPO plans and cuts a deal with Affimed
Nov. 3, 2022
Building a biotech in a downturn: 3 lessons from VCs and startup CEOs
Nov. 3, 2022
Armed with $120M, HI-Bio joins race to develop better autoimmune disease drugs
Nov. 1, 2022
An unusual alliance opens a gene and cell therapy hub outside Boston
Oct. 27, 2022
Verge Genomics’ Alice Zhang on a young biotech founder’s ‘superpower’ and going from target to drug
Oct. 25, 2022
Prime Medicine raises $175M in one of the year’s largest biotech IPOs
Oct. 20, 2022
A startup plans an IPO to give a shelved Lilly drug another shot
Oct. 19, 2022
Treeline Bio deepens investor roots with fresh funding for cancer drug research
Oct. 17, 2022
Covalent drugs take the stage — again — in Atlas Venture’s latest startup
Oct. 14, 2022
Ascidian starts up with $50M and a twist on RNA editing
Oct. 12, 2022
Brain disease startup Neumora draws more funding for ambitious research plan
Oct. 11, 2022
New TYK2 inhibitors: a growing race to top Bristol Myers
Oct. 11, 2022
A Flagship startup secures $121M in new funding
Oct. 4, 2022
Incyte, branching out in dermatology, to buy startup Villaris
Oct. 3, 2022
Ventus sells its lead drug candidate to Novo Nordisk
Sept. 29, 2022
Sudo joins a wave of startups taking aim at Bristol Myers’ new skin disease drug
Sept. 28, 2022
Perlara CEO Ethan Perlstein on reviving a biotech and building a ‘Y Combinator of rare diseases’
Sept. 27, 2022
Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street
Sept. 21, 2022
Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch
Sept. 19, 2022
Acelyrin sets hopes high for arthritis drug with $300M fundraise
Sept. 14, 2022
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
Sept. 12, 2022
Mitochondrial drugs, with a twist: Pretzel Therapeutics launches with $72.5M in funding
Sept. 12, 2022
Beam-linked startup launches with an eye on the next generation of RNA drugs
Sept. 7, 2022
Drugging RNA with pills: small molecules for a big frontier
Sept. 6, 2022
Atlas Venture’s Bruce Booth on testing the IPO waters and putting the ‘tech’ in biotech
Aug. 30, 2022
Bluejay raises $41M to bring hepatitis B drugs to clinical testing
Aug. 19, 2022
Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise
Aug. 16, 2022
Gemini’s fall gives Disc a way around biotech’s IPO slump
Aug. 10, 2022
A biotech startup gives Merck its next shot at treating Alzheimer’s
Aug. 9, 2022
How a small UK biotech ended up in Gilead’s hands
Aug. 5, 2022
Biotech IPOs are the industry’s lifeblood. Track how they’re performing.
Oct. 26, 2020

Industry Dive is an Informa TechTarget business.

This website is owned and operated by Informa TechTarget, part of a global network that informs, influences and connects the world's technology buyers and sellers. All copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.'s registered office is 275 Grove St. Newton, MA 02466.

Don't miss tomorrow's biopharma industry news

Gwendolyn Wu

Get in touch

261 articles by Gwendolyn Wu